Srihari Gopal

Summary

Publications

  1. ncbi request reprint Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA
    J Clin Psychiatry 66:1016-20. 2005
  2. pmc A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
    Danielle Coppola
    Janssen Research and Development, LLC, Raritan, New Jersey, USA
    BMC Psychiatry 12:26. 2012
  3. doi request reprint Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
    J Clin Psychopharmacol 33:157-61. 2013
  4. doi request reprint A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Gahan Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:218-26. 2011
  5. doi request reprint Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Int Clin Psychopharmacol 25:247-56. 2010
  6. doi request reprint Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
    Mahesh N Samtani
    Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
    CNS Drugs 25:829-45. 2011
  7. pmc Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
    Mahesh N Samtani
    Janssen Research and Development, LLC, NJ, USA
    Neuropsychiatr Dis Treat 9:721-30. 2013
  8. doi request reprint A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08560, USA
    J Clin Psychopharmacol 30:235-44. 2010
  9. pmc Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
    Neuropsychiatr Dis Treat 7:93-101. 2011
  10. pmc Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases
    Larry Alphs
    Ortho McNeil Janssen Scientific Affairs, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Curr Drug Saf 6:43-5. 2011

Detail Information

Publications13

  1. ncbi request reprint Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA
    J Clin Psychiatry 66:1016-20. 2005
    ..The purpose of this analysis was to assess rates of symptomatic remission in patients with bipolar mania receiving risperidone in a double-blind, parallel-group, multicenter, placebo-controlled trial conducted in India...
  2. pmc A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
    Danielle Coppola
    Janssen Research and Development, LLC, Raritan, New Jersey, USA
    BMC Psychiatry 12:26. 2012
    ..This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [234 mg]) in stable patients with schizophrenia over a 1-year period...
  3. doi request reprint Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
    J Clin Psychopharmacol 33:157-61. 2013
    ..Apart from events described in existing product labeling, no new safety findings emerged...
  4. doi request reprint A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Gahan Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:218-26. 2011
    ..4 [-1.62;2.38], per-protocol analysis set [primary analysis]). The tolerability and safety of PP was generally similar to RIS-LAI with no new safety or tolerability findings...
  5. doi request reprint Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Int Clin Psychopharmacol 25:247-56. 2010
    ..than placebo (>or=5% difference) were headache, vomiting, extremity pain, and injection site pain. Treatment with paliperidone palmitate (100 mg eq.) was efficacious and all doses tested were tolerable...
  6. doi request reprint Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
    Mahesh N Samtani
    Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
    CNS Drugs 25:829-45. 2011
    ..Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic...
  7. pmc Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
    Mahesh N Samtani
    Janssen Research and Development, LLC, NJ, USA
    Neuropsychiatr Dis Treat 9:721-30. 2013
    ..Recently, expansion of the day 8 dosing window from ±2 to ±4 days has been approved in the United States based on results obtained from the model-based simulations and review of safety data presented here...
  8. doi request reprint A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08560, USA
    J Clin Psychopharmacol 30:235-44. 2010
    ..6% vs 0.0%), and myalgia (1.0% vs 0.0%). The paliperidone palmitate treatment was efficacious and generally tolerated across the dose range (25, 100, or 150 mg eq.) in adult patients with acutely exacerbated schizophrenia...
  9. pmc Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
    Neuropsychiatr Dis Treat 7:93-101. 2011
    ....
  10. pmc Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases
    Larry Alphs
    Ortho McNeil Janssen Scientific Affairs, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Curr Drug Saf 6:43-5. 2011
    ..Examination of these prospective databases finds no evidence that risperidone LAI and paliperidone palmitate are associated with PDSS and suggest that findings seen with another antipsychotic LAI are not generalizable...
  11. doi request reprint Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, USA
    Schizophr Res 116:107-17. 2010
    ..We assessed efficacy and tolerability of the injectable atypical antipsychotic paliperidone palmitate in delaying time-to-relapse in adults with schizophrenia...
  12. doi request reprint Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention
    Deborah Nicholl
    Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ 08869, USA
    Curr Med Res Opin 26:1471-84. 2010
    ....
  13. doi request reprint Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ, USA
    Prog Neuropsychopharmacol Biol Psychiatry 33:1022-31. 2009
    ..Paliperidone palmitate treatment was tolerated, irrespective of injection site, and thus could offer the choice of administration into either the deltoid or gluteal muscle to meet patient and physician preference...